Braidwell’s Immunogen Inc IMGN Stock Holding History

Braidwell’s Portfolio IMGN Stock Details IMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-3,474,497	Closed	-$17.2M	–	100
2022 Q4	$17.2M	Buy	+3,474,497	New	+$18.8M	0.58%	62

Other funds holding IMGN

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Braidwell's IMGN Position: Q1 2023 in Review

Braidwell sold out of Immunogen Inc (IMGN) in Q1 2023, closing a stake of 3,474,497 shares — an estimated $17.2M sold.

Braidwell first reported a position in IMGN in Q4 2022 and held it in 1 quarter. The position peaked at $17.2M in Q4 2022. 190 funds tracked by Wall St. Rank hold IMGN as of Q1 2023.

Braidwell reported no remaining Immunogen Inc position as of Q1 2023 after selling out during the quarter.
Braidwell sold 3,474,497 Immunogen Inc shares in Q1 2023, an estimated $17.2M.
Braidwell first reported a position in Immunogen Inc in Q4 2022 and held it in 1 quarter.
Braidwell's Immunogen Inc position peaked at $17.2M in Q4 2022.
190 funds tracked by Wall St. Rank held Immunogen Inc as of Q1 2023.

Based on Braidwell's 13F filing for Q1 2023, filed 15 May 2023.